Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 16, 2026, 4:40 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 1,799 matching trials from the live ClinicalTrials.gov search.
Conditions
Melanoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Urothelial Carcinoma, Triple Negative Breast Cancer, HR+/HER2- Breast Cancer, Gastric Cancer
Interventions
Dose Escalation Doublet: Combination of NKTR-214 + nivolumab, Dose Expansion Doublet: Combination of NKTR-214 + nivolumab, Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab, Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
557 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
22
States / cities
La Jolla, California • Los Angeles, California • Stanford, California + 17 more
Conditions
Kidney Cancer, Metastatic Cancer
Interventions
sargramostim
Biological
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2013
U.S. locations
22
States / cities
Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 18 more
Conditions
Clear Cell Renal Cell Carcinoma
Interventions
X4P-001, Nivolumab
Drug
Lead sponsor
X4 Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Boston, Massachusetts • Hackensack, New Jersey + 1 more
Conditions
Locally Advanced Solid Tumor
Interventions
TNG462, Pembrolizumab
Drug
Lead sponsor
Tango Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
15
States / cities
Palo Alto, California • Grand Junction, Colorado • Lake Mary, Florida + 11 more
Conditions
Brain and Central Nervous System Tumors, Kidney Cancer, Liver Cancer, Retinoblastoma, Sarcoma
Interventions
filgrastim, busulfan, etoposide, ifosfamide, melphalan, thiotepa, stem cell transplantation, tomotherapy, total marrow irradiation, Mesna, Whole lung radiation
Biological · Drug · Procedure + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Recurrent Melanoma, Recurrent Renal Cell Cancer, Stage III Melanoma, Stage IV Melanoma, Stage IV Renal Cell Cancer
Interventions
recombinant interferon alfa-2b, amifostine/azacitidine
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Metastatic Castration-resistant Prostrate Cancer, Renal Cell Carcinoma, Metastatic Melanoma, Non-small Cell Lung Cancer
Interventions
BMS-936558 (MDX-1106)
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
13
States / cities
Scottsdale, Arizona • New Haven, Connecticut • Tampa, Florida + 7 more
Conditions
Kidney Cancer, Melanoma (Skin)
Interventions
recombinant CD40-ligand, recombinant flt3 ligand
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Pancreatic Adenocarcinoma Non-resectable, Pancreatic Adenocarcinoma Metastatic, Colorectal Cancer Metastatic
Interventions
RENCA macrobeads
Biological
Lead sponsor
The Rogosin Institute
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
New York, New York
Conditions
Metastatic Renal Cell Carcinoma
Interventions
DC vaccine, Bevacizumab, IL-2, IFN
Biological · Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Lebanon, New Hampshire
Conditions
Benign Kidney Neoplasm, Kidney Neoplasm, Renal Cell Cancer
Interventions
Hyperpolarized Carbon C 13 Pyruvate, Magnetic Resonance Imaging, Hyperpolarized 13C,15N2-urea
Drug · Procedure
Lead sponsor
Zhen Wang, MD
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
San Francisco, California
Conditions
Melanoma
Interventions
Blood Draw
Other
Lead sponsor
Wolfram Samlowski
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Las Vegas, Nevada
Conditions
Brain Tumor, Brain Metastases, Brain Cancer, Metastatic Lung Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Colon Cancer, Metastatic Kidney Cancer
Interventions
CALM, Treatment as usual
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
Carcinoma, Renal Cell, Melanoma
Interventions
Pembrolizumab, Interleukin-2
Drug
Lead sponsor
William Grosh, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Marginal Zone B Cell Lymphoma), Any T-cell Malignancy, Solid Tumors (Metastatic Melanoma, Renal (Clear) Cell Carcinoma, Hormone-refractory Prostate Adenocarcinoma, Ovarian Cancer, Colorectal Adenocarcinoma, Non-small Cell Lung Cancer), Burkett's Lymphoma, Primary Lymphoma of the Central Nervous System
Interventions
CDX-1127
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
10
States / cities
Scottsdale, Arizona • Stanford, California • Rochester, Minnesota + 7 more
Conditions
Kidney Cancer
Interventions
MDX 1411
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
7
States / cities
Boston, Massachusetts • Detroit, Michigan • Las Vegas, Nevada + 4 more
Conditions
Childhood Atypical Teratoid/Rhabdoid Tumor, Rhabdoid Tumor of the Kidney
Interventions
Laboratory Biomarker Analysis
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Brain and Central Nervous System Tumors, Breast Cancer, Kidney Cancer, Lung Cancer, Lymphoma, Melanoma (Skin), Ovarian Cancer, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
carboxyamidotriazole, paclitaxel
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2006
U.S. locations
2
States / cities
Bethesda, Maryland
Conditions
Papillary Thyroid Cancer, Follicular Thyroid Cancer, Huerthle Cell Thyroid Cancer, Renal Cell Carcinoma
Interventions
rosiglitazone, XL184
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
5
States / cities
Duarte, California • Boston, Massachusetts • The Bronx, New York + 2 more
Conditions
Renal Cell Carcinoma
Interventions
Axitinib, Avelumab, Pembrolizumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
481 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
New York, New York
Conditions
Head and Neck Neoplasms, Pheochromocytoma, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell
Interventions
Fostamatinib disodium
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Invasive Ductal Breast Carcinoma, Invasive Ductal Breast Carcinoma Stage IV, Lobular Breast Carcinoma, Lobular Breast Carcinoma Stage IV, Non Small Cell Lung Cancer, NSCLC, Gastrointestinal Cancer, Gastrointestinal Squamous Cell Cancer, Gastrointestinal Adenocarcinoma, Pancreatic Cancer, Bladder Cancer, Renal Cell Carcinoma, Melanoma, Sarcoma, Metastatic Solid Tumor
Interventions
Palliative radiotherapy
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Conditions
Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, Endometrial Cancer, Esophageal Cancer, Gastric Cancer, GastroEsophageal Cancer, Head and Neck Cancer, Hepatocellular Cancer, Non-small Cell Lung Cancer, Pancreatic Cancer, Prostate Cancer, Rectal Cancer, Renal Cancer, Thyroid Cancer, Urothelial Carcinoma (UC), Cholangiocarcinoma, Mesothelioma, Gallbladder Cancer, Ovarian Cancer
Interventions
MDX2001
Drug
Lead sponsor
ModeX Therapeutics, An OPKO Health Company
Industry
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
6
States / cities
Denver, Colorado • Miami, Florida • Boston, Massachusetts + 3 more
Conditions
Advanced Kidney Carcinoma, Advanced Renal Cell Carcinoma, Hereditary Leiomyomatosis and Renal Cell Carcinoma, Metastatic Kidney Carcinoma, Metastatic Renal Cell Carcinoma, Skin Leiomyoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Uterine Corpus Leiomyoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Mercaptopurine, Questionnaire Administration, Skin Biopsy
Procedure · Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Los Angeles, California